uniQure (NASDAQ:QURE) Stock Rating Lowered by Wall Street Zen

uniQure (NASDAQ:QURE - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday.

Several other equities analysts have also weighed in on QURE. Wells Fargo & Company cut their target price on uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a report on Friday, February 28th. Cantor Fitzgerald upgraded uniQure to a "strong-buy" rating in a report on Monday, May 19th. HC Wainwright restated a "buy" rating and set a $70.00 target price on shares of uniQure in a report on Thursday, May 29th. Chardan Capital restated a "buy" rating and set a $38.00 target price on shares of uniQure in a report on Friday, May 30th. Finally, Guggenheim restated a "buy" rating and set a $28.00 target price on shares of uniQure in a report on Monday, May 12th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, uniQure currently has a consensus rating of "Moderate Buy" and a consensus price target of $37.82.

uniQure Stock Performance

Shares of uniQure stock opened at $15.34 on Friday. The stock has a market cap of $840.26 million, a PE ratio of -3.09 and a beta of 0.08. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The business has a fifty day simple moving average of $13.59 and a 200-day simple moving average of $13.55.

uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.07) by $0.25. The firm had revenue of $1.57 million during the quarter, compared to analysts' expectations of $5.93 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. On average, sell-side analysts anticipate that uniQure will post -3.75 EPS for the current fiscal year.

Hedge Funds Weigh In On uniQure

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vestal Point Capital LP increased its stake in uniQure by 58.4% during the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock valued at $50,801,000 after acquiring an additional 1,767,572 shares during the period. Nantahala Capital Management LLC increased its stake in uniQure by 3.8% during the first quarter. Nantahala Capital Management LLC now owns 2,755,962 shares of the biotechnology company's stock valued at $29,213,000 after acquiring an additional 101,598 shares during the period. Aberdeen Group plc increased its stake in uniQure by 46.8% during the first quarter. Aberdeen Group plc now owns 2,215,551 shares of the biotechnology company's stock valued at $23,485,000 after acquiring an additional 706,216 shares during the period. Avoro Capital Advisors LLC bought a new position in uniQure during the fourth quarter valued at about $38,410,000. Finally, Franklin Resources Inc. increased its stake in uniQure by 33.1% during the fourth quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company's stock valued at $35,103,000 after acquiring an additional 494,726 shares during the period. 78.83% of the stock is currently owned by institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.